B
Bull
Bull · 25%RVTY
$80.72
Scenario price
$128.800
-0.902 (-0.70%)At close
Loading chart…
- High
- 130.070
- Open
- 128.570
- VWAP
- 128.71
- Vol
- 1.58M
- Mkt Cap
- 13.04B
- Low
- 127.260
- Amount
- 202.88M
- EV/EBITDA, TTM
- 18.17
Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
AI analysis of Revvity Inc (RVTY)
buyRevvity Inc is a good buy right now due to its current price of $128.80, which is below the analyst price target of $130, indicating potential upside. Additionally, the company has shown a strong year-to-date change of +31.23% and a solid gross margin of 57.13% in Q2 2026, suggesting robust profitability. However, the main risk is the recent decline in net profit to $51.82 million, down from $53.95 million, which could impact investor confidence.
Valuation Metrics
The current forward P/E ratio for Revvity Inc (RVTY) is 23.75, compared to its 5-year average forward P/E of 22.19.
Alphio AI Price Scenarios for RVTY
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding RVTY
Events Timeline
News
RVTY FAQ — answered by Alphio AI
Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Revvity Inc is a good buy right now due to its current price of $128.80, which is below the analyst price target of $130, indicating potential upside. Additionally, the company has shown a strong year-to-date change of +31.23% and a solid gross margin of 57.13% in Q2 2026, suggesting robust profitability. However, the main risk is the recent decline in net profit to $51.82 million, down from $53.95 million, which could impact investor confidence.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。